Altimmune Announces Q3 Results, Global PERFORMA Trial Progresses
Altimmune reported $480 million in cash as of September 30, 2026, and announced topline data readouts for the RESTORE ALD trial in H2 2027 and PERFORMA in 2029, with a Phase 2 RECLAIM study supporting an AUD program.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed